Flutazolam
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Coreminal (JP) |
| Other names | 13-chloro- 2-(2-fluorophenyl)- 9-(2-hydroxyethyl)- 3-oxa- 6,9-diazatricyclo[8.4.0.02,6] tetradeca-1(10),11,13- trien- 8-one |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Elimination half-life | 3.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H18ClFN2O3 |
| Molar mass | 376.809 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Flutazolam[1] (Coreminal, MS-4101) is a drug which is a benzodiazepine derivative. It was invented in Japan, and this is the main country in which it has been used medically. It has sedative, muscle relaxant, anticonvulsant, and anxiolytic effects similar to those produced by other benzodiazepine derivatives, and though it's around the same potency as diazepam, it produces a more marked sedation and impaired coordination. It is indicated for the treatment of insomnia.[2]
Flutazolam is closely related in structure to another benzodiazepine, haloxazolam.[3][4]
See also
References
- ^ DE Patent 1952486
- ^ Mitsushima T, Ueki S. Psychopharmacological effects of flutazolam (MS-4101). Nippon Yakurigaku Zasshi. 1978 Nov;74(8):959-79. (Japanese).
- ^ Kuwayama T, Kurono Y, Muramatsu T, Yashiro T, Ikeda K. The behavior of 1,4-benzodiazepine drugs in acidic media. V. Kinetics of hydrolysis of flutazolam and haloxazolam in aqueous solution. Chemical and Pharmaceutical Bulletin (Tokyo). 1986 Jan;34(1):320-6.
- ^ Yashiro T, Kuwayama T, Kawazura H, Suzuki T. The behavior of 1,4-benzodiazepine drugs in acidic media. IX. Effect of hydrolyzate of flutazolam on the central nervous system. Journal of the Pharmaceutical Society of Japan. 1987 Oct;107(10):830-4. (Japanese).